In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
386 News Items found
Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in <i>JAMA Oncology</i>.
GSK Dean Michael Overholtzer stands at the podium
Event
Virtual Convocation and Commencement Ceremony Honors Graduates and Award Winners

Memorial Sloan Kettering’s 42nd annual ceremony recognized graduates and award winners with a virtual ceremony.
Close up of an MSK researcher's hands and arms handling test tubes in the lab.
Gerstner Sloan Kettering Graduate Students Receive 2024-2025 Fellowships

Nine GSK PhD students were awarded competitive fellowships from prestigious external agencies such as the National Cancer Institute (NCI) and National Science Foundation (NSF).
Announcement
7 Gerstner Sloan Kettering Students Prepare to Graduate

Seven students will be awarded PhD degrees on May 19, 2021, from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), an innovative doctoral program that prepares the next generation of basic laboratory scientists to work in research areas related to human disease with a focus on cancer.
Dr. Sandra D'Angelo
In the Clinic
FDA Approves First Engineered Cell Therapy for Treating Rare Sarcoma

The FDA has approved an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. The clinical trials resulting in the drug’s approval were led by Dr. Sandra D’Angelo of MSK.
New Study Looks at Low-Dose Radiation That Could Make CAR T Cell Therapy More Effective

A preclinical study published in the journal Molecular Therapy by researchers at Memorial Sloan Kettering (MSK) provides evidence that radiation therapy could improve the efficacy of CAR T cell therapy for solid tumors.
Close up of gloved hands working in a lab
MSK Research Highlights September 29, 2023

New research from MSK develops a method for analyzing cancer cells that survive treatment for acute myeloid leukemia; identifies a transcription factor that orchestrates natural killer cell response; and finds vepafestinib is a promising therapeutic for the treatment of RET-driven cancers.
A researcher working in an MSK lab
MSK Research Highlights, April 23, 2025

New MSK research identifies a rare cell population responsible for AML persistence and resistance to therapy; sheds new light on early brain development; and investigates how other health conditions can increase cancer risk in midlife. MSK clinical trials also supported the recent approval of the targeted drug larotrectinib by the FDA.
Perry Ortiz surrounded by his wife, daughter, and two sons
Celebrating Hispanic and Latino Heritage Month: Perry Ortiz

Perry Ortiz doesn’t remember having a seizure in 2016. Or being rushed to an operating room, where doctors confirmed Perry — a security supervisor at M...
A lab coat with an MSK logo hangs on a hook
Meet the 2025 Graduates of the Gerstner Sloan Kettering Graduate School

Fourteen young scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 14, 2025, as part of Memorial Sloan Kettering’s 46th annual academic convocation.